EE04039B1 - Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine - Google Patents

Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine

Info

Publication number
EE04039B1
EE04039B1 EE9700187A EE9700187A EE04039B1 EE 04039 B1 EE04039 B1 EE 04039B1 EE 9700187 A EE9700187 A EE 9700187A EE 9700187 A EE9700187 A EE 9700187A EE 04039 B1 EE04039 B1 EE 04039B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
preparation
oral administration
active ingredient
buccal
Prior art date
Application number
EE9700187A
Other languages
English (en)
Estonian (et)
Other versions
EE9700187A (et
Inventor
Mary Brewer Francesca
Stewart Johnson Edward
Clarke Anthony
Original Assignee
R.P. Scherer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04039(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9504235.4A external-priority patent/GB9504235D0/en
Application filed by R.P. Scherer Limited filed Critical R.P. Scherer Limited
Publication of EE9700187A publication Critical patent/EE9700187A/xx
Publication of EE04039B1 publication Critical patent/EE04039B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
EE9700187A 1995-03-02 1996-03-01 Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine EE04039B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9504235.4A GB9504235D0 (en) 1995-03-02 1995-03-02 Pharmaceutical compositon
GBGB9517063.5A GB9517063D0 (en) 1995-03-02 1995-08-18 Pharmaceutical composition
PCT/GB1996/000484 WO1996026720A1 (en) 1995-03-02 1996-03-01 Pharmaceutical compositions comprising monoamine oxidase b inhibitors

Publications (2)

Publication Number Publication Date
EE9700187A EE9700187A (et) 1998-02-16
EE04039B1 true EE04039B1 (et) 2003-06-16

Family

ID=26306612

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700187A EE04039B1 (et) 1995-03-02 1996-03-01 Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine

Country Status (26)

Country Link
US (3) US20010021722A1 (pl)
EP (1) EP0814789B2 (pl)
JP (1) JP3273141B2 (pl)
CN (1) CN1171586C (pl)
AT (1) ATE241346T1 (pl)
AU (1) AU702161B2 (pl)
BG (1) BG63862B1 (pl)
BR (1) BR9607057A (pl)
CA (1) CA2214026C (pl)
CZ (1) CZ297382B6 (pl)
DE (1) DE69628415T3 (pl)
DK (1) DK0814789T4 (pl)
EE (1) EE04039B1 (pl)
ES (1) ES2199283T5 (pl)
GE (1) GEP20012374B (pl)
HU (1) HU228852B1 (pl)
IS (1) IS2789B (pl)
MX (1) MX9706647A (pl)
NO (1) NO316804B1 (pl)
NZ (2) NZ329471A (pl)
PL (1) PL183266B1 (pl)
PT (1) PT814789E (pl)
SI (1) SI0814789T2 (pl)
SK (1) SK284383B6 (pl)
TR (1) TR199700878T1 (pl)
WO (1) WO1996026720A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
WO1996024346A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
CA2236368C (en) * 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
GB9717770D0 (en) * 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
GB9802088D0 (en) * 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
EP1171146B1 (en) * 1999-04-21 2004-06-23 Yuyu Inc. Pharmaceutical compositions containing selegiline and ginkgo biloba extract useful for treating dementia
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
WO2006057912A2 (en) * 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
US7956220B2 (en) 2005-07-01 2011-06-07 Jenrin Discovery MAO-B inhibitors useful for treating obesity
CN1911211B (zh) * 2006-08-25 2010-04-14 重庆医药工业研究院有限责任公司 雷沙吉兰口服固体制剂
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20070190187A1 (en) * 2006-09-07 2007-08-16 Kneller Bruce W Formulation for enhanced delivery of phenethylamine
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
US20120058962A1 (en) * 2009-05-20 2012-03-08 Lingual Conseqna Pty Ltd. Buccal and/or sublingual therapeutic formulation
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
CN109152841A (zh) 2016-03-26 2019-01-04 雷迪博士实验室有限公司 N-炔丙胺衍生物的药物组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4454158A (en) * 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
IE53696B1 (en) * 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
JP2660419B2 (ja) * 1988-04-02 1997-10-08 旭電化工業株式会社 安定化された合成樹脂組成物
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192550A (en) † 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
GB9017610D0 (en) * 1990-08-10 1990-09-26 Erba Carlo Spa Antiparkinson mao reversible inhibitor
NZ246091A (en) † 1991-12-24 1995-08-28 Yamanouchi Pharma Co Ltd Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1993025197A1 (en) † 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
CA2236368C (en) † 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline

Also Published As

Publication number Publication date
AU702161B2 (en) 1999-02-18
DE69628415T3 (de) 2008-06-26
NO974010L (no) 1997-10-30
EE9700187A (et) 1998-02-16
NO974010D0 (no) 1997-09-01
CA2214026C (en) 2007-10-16
NZ329471A (en) 1999-10-28
SK284383B6 (sk) 2005-02-04
WO1996026720A1 (en) 1996-09-06
DE69628415D1 (de) 2003-07-03
HU228852B1 (en) 2013-06-28
US20010021722A1 (en) 2001-09-13
BG63862B1 (bg) 2003-04-30
CA2214026A1 (en) 1996-09-06
BR9607057A (pt) 1998-06-09
AU4884696A (en) 1996-09-18
BG101937A (en) 1998-07-31
NO316804B1 (no) 2004-05-18
PL322046A1 (en) 1998-01-05
PL183266B1 (pl) 2002-06-28
ES2199283T5 (es) 2008-05-16
EP0814789A1 (en) 1998-01-07
TR199700878T1 (xx) 1998-01-21
CN1178461A (zh) 1998-04-08
NZ302723A (en) 1998-04-27
GEP20012374B (en) 2001-03-25
SK115897A3 (en) 1998-03-04
EP0814789B2 (en) 2008-01-09
ES2199283T3 (es) 2004-02-16
DE69628415T2 (de) 2004-03-11
SI0814789T1 (en) 2003-12-31
IS4553A (is) 1997-08-27
CZ297382B6 (cs) 2006-11-15
US20040091525A1 (en) 2004-05-13
JP3273141B2 (ja) 2002-04-08
DK0814789T4 (da) 2008-05-19
EP0814789B1 (en) 2003-05-28
IS2789B (is) 2012-06-15
CN1171586C (zh) 2004-10-20
JPH10506409A (ja) 1998-06-23
MX9706647A (es) 1998-06-30
US20080187573A1 (en) 2008-08-07
DK0814789T3 (da) 2003-09-01
HUP9801227A2 (hu) 1999-06-28
PT814789E (pt) 2003-09-30
ATE241346T1 (de) 2003-06-15
CZ270597A3 (cs) 1998-01-14
HUP9801227A3 (en) 2000-02-28
SI0814789T2 (sl) 2008-04-30

Similar Documents

Publication Publication Date Title
EE04039B1 (et) Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine
ATE525061T1 (de) Feste selbst-haftende zusammensetzungen zur topischen behandlung von störungen der mundschleimhaut
DE69403656D1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
PT706398E (pt) Composicao farmaceutica contendo heparina fragmentos de heparina ou seus derivados em combinacao com esteres de glicerol
HUP9903544A2 (hu) Helyileg alkalmazható anesztetikus hatású gyógyszerkészítmény
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
EE03526B1 (et) Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine
DE69802113D1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
WO2001074396A8 (en) Composition and method for promoting oral health
NO20024673D0 (no) Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
MA25576A1 (fr) NOUVELLE FORME GALéNIQUE ORALE LIBéRATION PROLONGéE DE LA MOLSIDOMINE.
MD940244A (ro) Derivaţi noi ai tetrazolului, procedeu de obţinere a lor şi compoziţie farmaceutică pe baza lor
ATE342060T1 (de) Pharmazeutische zusammensetzungen zur behandlung von herpes zoster
JP2003502270A5 (pl)
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231